Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a recently-listed clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the partial exercise of the Over-Allotment Option by Kempen & Co N.V. acting on behalf of the Underwriters and the end of the stabilisation period in relation to its initial public offering (the “IPO” or the “Offering”).
Kiadis Pharma had granted the Stabilisation Manager an option to purchase up to 392,045 additional shares at the Offer Price of EUR 12.50 to cover potential over-allotments or short positions in connection with the Offering, which option was exercisable for a period of 30 calendar days as from the first day of listing of the shares on Euronext Amsterdam and Euronext Brussels (i.e. 2 July 2015) (the “Over-Allotment Option”)
On 31 July 2015 the Stabilisation Manager exercised the Over-Allotment option for 163,500 shares, raising additional gross proceeds of € 2.0 million for Kiadis Pharma. As a result, the total number of shares sold by Kiadis Pharma in the IPO amounts to 2,777,136 shares, representing total gross proceeds of € 34.7 million from the Offering.
The stabilisation period commenced on 2 July 2015 and ended on 31 July 2015. The new shares will be listed on Euronext Amsterdam and Euronext Brussels on or about 5 August 2015 and rank pari passu with the existing shares.
